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of symptoms), economic (visits, use of drugs, diagnostic
tests, hospitalizations, productivity losses), and quality of
life (EQ-5D and QOLRAD) variables. We evaluated the
costs of the medical resources and the loss of productiv-
ity in the perspective of the society. We report on costs
and EQ-5D. RESULTS: A total of 317 patients were
enrolled, the mean age was 59 years old, and the 58% of
the patients were female. The average cost per patient per
month was €60.95 and drugs accounted for 65% of total
cost. Indirect costs, expressed in terms of days lost at
work or inability to do usual activities, were about 0.5
days per patient. Patients who reported chest pain and
epigastric pain were more costly compared to those 
who did not (P £ 0.01, Mann-Whitney U test). A strong
impairment in the Health Related Quality of Life was also
documented: patients reported an average value 64.4 in
the 0–100 Visual Analogue Scale of EuroQol (EQ-VAS),
signiﬁcantly lower compared to general population. 
The EQ-proﬁle indicated that “pain/disconfort” and
“anxiety/depression” were the most impaired domains.
CONCLUSIONS: This is the ﬁrst Italian study about
costs and HRQol of GERD in which patients are enrolled
by GPs. The study highlights the relevant economic,
social, and quality of life burden of GERD.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD)
is one of the most common chronic disorders of the gas-
trointestinal tract. The aim of the study was to evaluate
the cost of illness and the Health-Related Quality of Life
(HRQoL) in patients with GERD visited by gastroen-
terologists. METHODS: A cross-sectional observational
multicenter cost of illness study was conducted. Patients
were enrolled by gastroenterologists of three specialist
centers in Italy. Information about demographic charac-
teristics, symptoms (frequency and severity), resource use
(visits, drugs, clinical examinations and hospitalizations)
and productivity losses was obtained through an ad 
hoc questionnaire. We evaluated costs of the medical
resources and loss of productivity in the perspective of
the Italian society. To evaluate the HRQoL we used a
battery of two questionnaires (SF-36 and EQ-5D).
RESULTS: Ninety-one patients were enrolled, the mean
age was 52 years old and the 49% of the patients were
males. The average cost per patient-month was €75.42
and hospitalizations accounted for the 34% of total
medical costs. Indirect costs, expressed in terms of lost
productivity, were about 0.2 working days lost per
patient-month. Presence of chest pain and eructation was
associated with higher overall costs (P < 0.05). A strong
impairment in the HRQoL was also documented: SF-36
showed that “role-physical”, “bodily pain” and “role-
emotional” were the most impaired dimensions. These
results are consistent with those obtained with the EQ-
5D proﬁle. Frequency and intensity of symptoms were
signiﬁcantly associated with lower levels of HRQoL.
CONCLUSIONS: This is the ﬁrst study investigating cost
of care and HRQoL of patients with GERD in Italy. The
study highlights the relevant economic, social, and quality
of life burden of GERD.
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OBJECTIVES: Recently published data suggest that an
acceptable threshold of around £30,000 per quality
adjusted life year (QALY) gained is implicitly used in
NICE appraisals on cost-effectiveness of medical inter-
ventions. The objective of this analysis was to investigate
the sensitivity in drug prices during acute treatment of
reﬂux oesophagitis with esomeprazole 40mg or omepra-
zole 20mg by applying a £30,000 threshold in a 
cost-utility analysis. METHODS: Results from a cost-
effectiveness analysis based on clinical study data have
previously been published using a decision analysis model
that considered UK direct medical costs up to 8 weeks.
In the current analysis, this model was modiﬁed to include
utility values associated with having (0.69) or not having
reﬂux oesophagitis (0.84). Utility values were derived
from a recent study using the rating scale method in
patients with gastro-oesophageal reﬂux disease. An addi-
tional analysis was made extending the model to a 16-
week time-frame in order to assess further costs and
effects of achieving treatment success or not during the
initial 8 weeks. Patient management assumptions were
based on a UK physician survey. RESULTS: When the
price of omeprazole was set to zero, the 8-week and 
the 16-week analyses resulted in around £27,700 and
£23,200 per QALY gained respectively by using
esomeprazole treatment. A sensitivity analysis indicated
results below the £30,000 threshold in most combina-
tions of different assumptions and scenarios while
holding the price of omeprazole constant at zero. In the
16-week analysis, esomeprazole treatment remained cost
saving (i.e. esomeprazole provided better effectiveness at
similar or lower costs) when the price of omeprazole was
reduced by around 45%. CONCLUSIONS: Applying an
acceptable threshold of £30,000 per QALY gained in a
cost-utility analysis of esomeprazole versus omeprazole in
the acute treatment of reﬂux oesophagitis indicates that
esomeprazole will remain cost-effective irrespective of
future generic omeprazole prices.
